Related Experiment Video
Updated: Aug 8, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Early diagnosis of smoldering acute lymphoblastic leukemia using immunological marker analysis
A C Knulst1, H J Adriaansen, K Hählen
1Department of Immunology, University Hospital Dijkzigt/Erasmus University, Rotterdam, The Netherlands.
Insights
Immunological marker analysis using CD10 and TdT aids in early diagnosis of smoldering acute lymphoblastic leukemia (ALL), especially in cases with hypoplastic bone marrow where cytomorphology is inconclusive.
Area of Science:
- Pediatric Hematology Oncology
- Immunology
- Molecular Diagnostics
Background:
- Acute lymphoblastic leukemia (ALL) diagnosis relies on cytomorphological analysis of bone marrow and peripheral blood.
- Challenges arise when initial cytomorphology is inconclusive, particularly in cases with hypoplastic bone marrow.
Observation:
- Immunological marker analysis was performed on 164 children with ALL over 9 years.
- Four children presented with inconclusive cytomorphological diagnoses.
- High frequencies of CD10+, TdT+ cells were detected in these patients' bone marrow and peripheral blood.
Findings:
- CD10 and TdT double immunological marker analysis revealed significantly elevated CD10+, TdT+ cell frequencies in patients with initially inconclusive ALL diagnoses compared to healthy controls.
- These elevated levels were observed even in cases with hypoplastic bone marrow.
- Subsequent cytomorphological diagnosis of ALL confirmed the initial suspicion, with further increases in CD10+, TdT+ cells.
Implications:
- CD10, TdT double immunological marker analysis is a valuable tool for the early detection of smoldering ALL.
- This method assists in diagnosing ALL in challenging cases, including those with hypoplastic bone marrow.
- Early diagnosis facilitates timely therapeutic interventions for pediatric ALL patients.
Abstract:
During a period of 9 years, we performed immunological marker analysis in 164 children with acute lymphoblastic leukemia. In four children the diagnosis acute leukemia could not be established by cytomorphological analysis of bone marrow and peripheral blood samples at initial presentation. In two of these four children a hypoplastic bone marrow was found, whereas the bone marrow of the other two children was normocellular. Using double immunological marker analysis, we detected high frequencies of CD10+, TdT+ cells in bone marrow (range: 18-53%) as well as peripheral blood (range: 0.04-19.5%). In control bone marrow and peripheral blood samples from healthy children, the frequency of CD10+, TdT+ cells does not exceed 10% and 0.03%, respectively. Based on the immunological data, a common acute lymphoblastic leukemia (ALL) was suspected. In addition, chromosome analysis revealed a high hyperdiploid (> 50 chromosomes) karyotype in three patients and t(9;22) in one patient. At 18 to 68 days after initial presentation, an ALL was diagnosed according to cytomorphological criteria in all four patients. At that time the percentage of CD10+, TdT+ cells in bone marrow and peripheral blood had increased significantly. One patient could be monitored frequently from initial presentation onwards. First a decline in the percentage of CD10+, TdT+ cells was found, although treatment consisted only of red blood cell transfusion and antibiotics. Subsequently the percentage of CD10+, TdT+ cells gradually increased until the morphological ALL diagnosis. These results illustrate that CD10, TdT double immunological marker analysis is a useful tool for early diagnosis of smoldering ALL in patients with a suspicious bone marrow, even when the bone marrow is hypoplastic.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018